Lenalidomide interactions
Full monograph for LenalidomideCheck it against another medicine
Medicines
401 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Adalimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Major | Synergy · Unknown | The risk of rhabdomyolysis may be increased during coadministration of lenalidomide with HMG-CoA reductase inhibitors (statins). The mechanism is unknown but…2 documented mechanisms | 12 sources — open the full entry |
| Atezolizumab | Major | Others | Coadministration of thalidomide or its analogs with a programmed death receptor-1 (PD-1) or programmed death ligand-1 (PD-L1) blocking antibody may increase… | 9 sources — open the full entry |
| Atorvastatin + Ezetimibe | Major | Synergy · Unknown | The risk of rhabdomyolysis may be increased during coadministration of lenalidomide with HMG-CoA reductase inhibitors (statins). The mechanism is unknown but…2 documented mechanisms | 12 sources — open the full entry |
| Atorvastatin Calcium | Major | Synergy | The risk of rhabdomyolysis may be increased during coadministration of lenalidomide with HMG-CoA reductase inhibitors (statins). The mechanism is unknown but… | 12 sources — open the full entry |
| Avelumab | Major | Others | Coadministration of thalidomide or its analogs with a programmed death receptor-1 (PD-1) or programmed death ligand-1 (PD-L1) blocking antibody may increase… | 9 sources — open the full entry |
| Baricitinib | Major | Synergy | Coadministration of baricitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 4 sources — open the full entry |
| Clozapine | Major | Synergy | Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. | 9 sources — open the full entry |
| Conjugated EstrogenCreamTablet | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1… | 6 sources — open the full entry |
| Conjugated Estrogen + Bazedoxifene | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1…2 documented mechanisms | 10 sources — open the full entry |
| Cyproterone Acetate + Ethinyl Estradiol | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as estrogens may potentiate the risk of venous thromboembolic events associated with the use… | 36 sources — open the full entry |
| Darbepoetin Alfa | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1… | 6 sources — open the full entry |
| Deferiprone | Major | Synergy | Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity… | 5 sources — open the full entry |
| Deucravacitinib | Major | Synergy | Coadministration of deucravacitinib with other immunosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. | 1 sources — open the full entry |
| Dienogest | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as estrogens may potentiate the risk of venous thromboembolic events associated with the use… | 2 sources — open the full entry |
| Dienogest + Estradiol Valerate | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as estrogens may potentiate the risk of venous thromboembolic events associated with the use…2 documented mechanisms | 8 sources — open the full entry |
| Drospirenone | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as estrogens may potentiate the risk of venous thromboembolic events associated with the use… | 36 sources — open the full entry |
| Drospirenone + Estetrol | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1…2 documented mechanisms | 40 sources — open the full entry |
| Drospirenone + Estradiol | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as estrogens may potentiate the risk of venous thromboembolic events associated with the use…2 documented mechanisms | 42 sources — open the full entry |
| Drospirenone + Ethinyl Estradiol0.02 mg0.03 mg | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as estrogens may potentiate the risk of venous thromboembolic events associated with the use…2 documented mechanisms | 36 sources — open the full entry |
| Drospirenone + Ethinyl Estradiol + Levomefolate | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as estrogens may potentiate the risk of venous thromboembolic events associated with the use…2 documented mechanisms | 36 sources — open the full entry |
| Erythropoietin Alfa | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1… | 6 sources — open the full entry |
| Erythropoietin Beta | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1… | 6 sources — open the full entry |
| Estradiolbasevaginal cream | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1… | 6 sources — open the full entry |
| Estradiol + Dydrogesterone | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1… | 6 sources — open the full entry |
| Estradiol Hemihydrate + Progesterone Micronized | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1… | 6 sources — open the full entry |
| Estradiol Valerate | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1… | 6 sources — open the full entry |
| Etanercept | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Ethinyl Estradiol + Desogestrel0.02 mg0.03 mg | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as estrogens may potentiate the risk of venous thromboembolic events associated with the use… | 36 sources — open the full entry |
| Ethinyl Estradiol + Gestodene | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as estrogens may potentiate the risk of venous thromboembolic events associated with the use… | 36 sources — open the full entry |
| Ethinyl Estradiol + Levonorgestrel + Ferrous Fumarate | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as estrogens may potentiate the risk of venous thromboembolic events associated with the use… | 36 sources — open the full entry |
| Ethinyl Estradiol + Lynestrenol0.0375 mg0.05 mg | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as estrogens may potentiate the risk of venous thromboembolic events associated with the use… | 36 sources — open the full entry |
| Fluvastatin | Major | Synergy | The risk of rhabdomyolysis may be increased during coadministration of lenalidomide with HMG-CoA reductase inhibitors (statins). The mechanism is unknown but… | 12 sources — open the full entry |
| Golimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Infliximab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Leflunomide | Major | Synergy | The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to… | 1 sources — open the full entry |
| Medroxyprogesterone AcetateInjectionTablet | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1… | 4 sources — open the full entry |
| Methoxy Polyethylene Glycol-Epoetin Beta | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1… | 4 sources — open the full entry |
| Nivolumab | Major | Others | Coadministration of thalidomide or its analogs with a programmed death receptor-1 (PD-1) or programmed death ligand-1 (PD-L1) blocking antibody may increase… | 9 sources — open the full entry |
| Norgestrel + Ethinyl Estradiol + Ferrous Fumarate | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as estrogens may potentiate the risk of venous thromboembolic events associated with the use… | 36 sources — open the full entry |
| Ospemifene | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1… | 6 sources — open the full entry |
| Pegylated Erythropoietin | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1… | 6 sources — open the full entry |
| Pembrolizumab | Major | Others | Coadministration of thalidomide or its analogs with a programmed death receptor-1 (PD-1) or programmed death ligand-1 (PD-L1) blocking antibody may increase… | 9 sources — open the full entry |
| Pitavastatin Calcium | Major | Synergy | The risk of rhabdomyolysis may be increased during coadministration of lenalidomide with HMG-CoA reductase inhibitors (statins). The mechanism is unknown but… | 12 sources — open the full entry |
| Pravastatin Sodium | Major | Synergy | The risk of rhabdomyolysis may be increased during coadministration of lenalidomide with HMG-CoA reductase inhibitors (statins). The mechanism is unknown but… | 12 sources — open the full entry |
| Relugolix + Estradiol + Norethindrone | Major | Synergy | Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1… | 6 sources — open the full entry |
| Rosuvastatin + Ezetimibe | Major | Synergy · Unknown | The risk of rhabdomyolysis may be increased during coadministration of lenalidomide with HMG-CoA reductase inhibitors (statins). The mechanism is unknown but…2 documented mechanisms | 12 sources — open the full entry |
| Rosuvastatin Calcium | Major | Synergy | The risk of rhabdomyolysis may be increased during coadministration of lenalidomide with HMG-CoA reductase inhibitors (statins). The mechanism is unknown but… | 12 sources — open the full entry |
| Rotavirus Vaccine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of… | 9 sources — open the full entry |
| Simvastatin | Major | Synergy | The risk of rhabdomyolysis may be increased during coadministration of lenalidomide with HMG-CoA reductase inhibitors (statins). The mechanism is unknown but… | 12 sources — open the full entry |
Conditions
Conditions in which Lenalidomide needs care, as documented in this source.
Anemia
ModerateSome miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia. Patients with these preexisting conditions should be monitored carefully. Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.
2 sources
- "Product Information. Vidaza (azacitidine)." Celgene Corporation (2004):
- "Product Information. Revlimid (lenalidomide)." Celgene Corporation (2006):
Kidney Diseases
ModerateLenalidomide is primarily excreted unchanged by the kidney. Adjustments to the starting dose are recommended in patients with moderate (CrCl 30-60 mL/min) or severe renal impairment (<30 mL/min), and in patients on dialysis.
1 source
- "Product Information. Revlimid (lenalidomide)." Celgene Corporation (2006):
Thromboembolism
ModerateVenous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboses are increased in patients using lenalidomide. Patients with known risk factors such as prior thrombosis, may be at greater risk and actions should be taken to minimize all other modifiable risk factors (e.g., smoking, hyperlipidemia, hypertension).
1 source
- "Product Information. Revlimid (lenalidomide)." Celgene Corporation (2006):